EDITORIALBidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?
REFERENCES (85)
- et al.
Managing conflict of interest in clinical practice
Mayo Clin Proc
(2007) Divergent views on managing clinical conflict of interest [letter]
Mayo Clin Proc
(2007)- et al.
Publication of market-driven research in medical journals [letter]
Mayo Clin Proc
(2006) Editor's note: industry support of articles published in Mayo Clinic Proceedings
Mayo Clin Proc
(2006)Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals
Mayo Clin Proc
(2009)- et al.
Correction: notice of duplicate publication
Mayo Clin Proc
(2000) Witness to a miracle: the initial cortisone trial: an interview with Richard Freyberg, MD
Mayo Clin Proc
(2001)The Nobel chronicles: 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)
Lancet
(2000)- et al.
Sponsorship, authorship and accountability
Lancet
(2001) - et al.
Sponsorship, authorship and accountability [in Spanish] [editorial]
Rev Esp Cardiol
(2001)
Clinical trial registration: a statement from the International Committee of Medical Journal Editors [editorial]
Lancet
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors
Lancet
Clinical trial registration: looking back and moving ahead [editorial]
Lancet
Conflict of interest in medical research, education and practice. Released April 28, 2009
Good publication practice for pharmaceutical companies
Curr Med Res Opin
“Good publication practice for pharmaceutical companies”: where are we now?
MedGenMed
Time to nip “seeding trials” in the bud
Arch Dermatol
Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?
PLoS Med
Ghost marketing: pharmaceutical companies and ghostwritten journal articles
Perspect Biol Med
Regulating academic industry research relationships-solving problems or stifling progress?
N Engl J Med
Financial associations of authors [editorial]
N Engl J Med
Conflict of interest: the new McCarthyism in science
JAMA
Pharmacology researchers receive 1988 Nobel Prize
JAMA
The 1988 Nobel Prize for Physiology or Medicine
Science
In celebration of a Nobel prize [editorial]
J Natl Cancer Inst
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
N Engl J Med
The New England Journal missed Vioxx warning signs
Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520-8 [editorial]
N Engl J Med
Sponsorship, authorship, and accountability. ICMJE Web site
Clinical trial registration. A statement from the International Committee of Medical Journal Editors. ICMJE Web site
ICMJE Web site. Is this clinical trial fully registered?: A statement from the International Committee of Medical Journal Editors
ICMJE Web site. Clinical trial registration. Looking back and moving ahead
Sponsorship, authorship and accountability [editorial]
JAMA
Sponsorship, authorship and accountability [editorial]
N Engl J Med
Sponsorship, authorship and accountability [editorial]
Ann Intern Med
Sponsorship, authorship and accountability [editorial]
CMAJ
Sponsorship, authorship and accountability [editorial]
Obstet Gynecol
International Committee of Medical Journal Editors. Sponsorship, authorship and accountability [editorial]
Med J Aust
Sponsorship, authorship and accountability [editorial]
Ugeskr Laeger
Sponsorship, authorship and accountability [editorial]
Arch Otolaryngol Head Neck Surg
Sponsorship, authorship and accountability [in Norwegian] [editorial]
Tidsskr Nor Laegeforen
Cited by (43)
Medical ethics, research and the pharmaceutical industry
2012, Reumatologia ClinicaTen recommendations for closing the credibility gap in reporting industry-sponsored clinical research: A joint journal and pharmaceutical industry perspective
2012, Mayo Clinic ProceedingsCitation Excerpt :These debates notwithstanding, however, editors and sponsors should support the use of the updated ICMJE Conflict of Interest Reporting Form19 and continue dialogue regarding its improvement. Furthermore, the same conflict of interest reporting standards should be applied uniformly to all authors, regardless of the source of research funding.20 To further enhance disclosure transparency and reduce the administrative burden on authors, all parties should also explore the feasibility of developing a centralized, publicly accessible disclosure database.21
Conflict of interest policies and disclosure requirements among European society of cardiology national cardiovascular journals
2012, Revista Espanola de CardiologiaConflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals
2012, Revista Portuguesa de CardiologiaCitation Excerpt :Subtle biases in design and interpretation may arise when a sponsor stands to gain from the report.17 Pharmaceutical and technological companies are responsible for most important advancements in medical knowledge.17–24 Patients, doctors, and society as a whole benefit from this unique effort and should be grateful for the research commitment by the industry.
COX-2 inhibition: What we learned-A controversial update on safety data
2013, Pain Medicine (United States)Citation Excerpt :In September 2009, Mayo Clinic Proceedings published both an article and an editorial on the financial and intangible incentives journals have to demonstrate bias against pharmaceutical industry research. This in turn generated a massive reader response, reflecting the enormity of this previously unrecognized issue [1–3]. The first step in reviewing c2sNSAID safety data would be defining what comprises a c2sNSAID.
Reading Between the Lines: Navigating Nuance in Medical Literature to Optimize Clinical Decision-Making and Health Care Outcomes
2023, Advances in Medical Education and Practice
Dr Lanier was a laboratory-based researcher at Mayo Clinic from 1983-2006 but currently focuses on clinical research. His research has been funded by multiple governmental, foundation, professional-association, and industry sources. Dr Lanier has not sought nor received industry funding for his research since becoming Editor-in-Chief of Mayo Clinic Proceedings in January 1999.